期刊文献+

吸入制剂空气动力学粒径分布测定法浅析 被引量:12

A review on the determination methods for the aerodynamic particle size distribution of the inhalation preparations
原文传递
导出
摘要 测定吸入制剂的粒径是确定粒子在呼吸道系统中空气动力学分布的重要方法。粒径测定的方法有级联撞击器法、激光衍射法、飞行时间光谱测定法等。尽管级联撞击器测定法步骤繁杂、耗时,但该测定法是国际公认、准确的方法并且是多国药典收载的法定方法。本文就采用级联撞击器法对吸入制剂进行空气动力学粒径分布的测定进行综述,包括该方法的原理和数据评估,不同吸入制剂对该方法的适用性及该方法的变异性。 Particle size of the orally inhaled drug products( OIPs) is widely accepted as an important factor in determining the aerodynamic deposition of particles within the respiratory system. Methods used for the particle size determinationinclude cascade impactor( CI),laser diffraction( LD),and time of flight spectrometry. As an accurate compendium method,the CI-based methods for measuring the aerodynamic particle size distribution( APSD) properties of OIP-produced aerosols are recognized by the regulatory agencies worldwide and adopted by various pharmacopoeias,although CI method is characterized by complex devices and time-consuming operations.The purpose of this review is to discuss the roles of CI in determining the APSD of OIPs,including its principle and data interpretation,suitability and variability of the CI method for the characterization of inhalation preparations.
出处 《中国新药杂志》 CAS CSCD 北大核心 2017年第12期1433-1438,共6页 Chinese Journal of New Drugs
基金 国家"重大新药创制"科技重大专项资助项目(化药制剂质量评价关键技术研究 吸入制剂有效性评价方法研究 2015ZX093001002009)
关键词 吸入给药 体外评价 空气动力学粒径分布 级联撞击器 inhalation administration in vitro evaluation aerodynamic particle size distribution cascade impactor
  • 相关文献

参考文献2

二级参考文献36

  • 1王长征.哮喘发病的“卫生学说”及有关的争议[J].中国呼吸与危重监护杂志,2005,4(5):397-398. 被引量:11
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8240
  • 3Shahiwala A, Misra A. A preliminary pharmacokinetie study of liposomal leuprolide dry powder inhaler: a technical note [J]. AAPS Pharm Sci Tech, 2005,6:E482-E486.
  • 4Zijlstra G S, Hinrichs W L, de Boer A H, et al. The role of particle engineering in relation to formulation and deagglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix [J]. Eur J Pharm Sci, 2004,23(2): 139-149.
  • 5Lizio R, Klenner T, Sarlikiotis A W, et al. Systemic delivery of cetrorelix to rats by a new aerosol delivery system[J]. Pharm Res, 2001,18(6):771-779.
  • 6Bai S, Gupta V, Ahsan F. Inhalable lactose-based dry powder formulations of low molecular weight heparin[J]. J Aerosol Med Pulm Drug Deliv, 2010,23(2):97-104.
  • 7Codrons V, Vanderbist F, Verbeeck R K, et al. Systemic delivery of parathyroid hormone(1-34) using inhalation dry powders in rats[J]. J Pharm Sci, 2003,92(5):938-950.
  • 8Codrons V, Vanderbist F, Ucakar B, et al. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs [J]. J Pharm Sci, 2004,93(5):1241-1252.
  • 9Clark A, Kuo M C, Newman S, et al. A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon ealcitonin [J]. Pharm Res, 2008,25 (7):1583- 1590.
  • 10Dumont J A, Bitonti A J, Clark D, et al. Delivery of an erythropoietin-Fe fusion protein by inhalation in humans through an immunoglobulin transport pathway[J]. J Aerosol Med, 2005, 18(3):294-303.

共引文献22

同被引文献76

引证文献12

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部